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Recessive mutations in MEGF10 are known to cause a congenital myopathy in humans. Two
mutations in the extracellular EGF-like domains of MEGF10, C326R and C774R, were associated with
decreased tyrosine phosphorylation of MEGF10 in vitro. Y1030 was identiﬁed to be the major
tyrosine phosphorylation site in MEGF10 and is phosphorylated at least in part by c-Src. Overexpres-
sion of wild-type MEGF10 enhanced C2C12 myoblast proliferation, while overexpression of Y1030F
mutated MEGF10 did not. We conclude that MEGF10-mediated signaling via tyrosine phosphoryla-
tion helps to regulate myoblast proliferation. Defects in this signaling pathway may contribute to
the disease mechanism of MEGF10 myopathy.
Structured summary of protein interactions:
c-Src physically interacts with MEGF10 by anti tag coimmunoprecipitation (1, 2, 3, 4)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cytoplasmic domainwith 13 tyrosine residues thatmay be involvedMutations inMEGF10were recently found to cause an autosomal
recessive skeletal muscle disease [1–3]. MEGF10 myopathy pa-
tients experience progressive congenital muscle weakness and
respiratory failure, without any signs of central nervous system
dysfunction [2,3]. MEGF10 is expressed in satellite cells of skeletal
muscle [4]. Satellite cells are muscle stem cells that play a key role
in muscle growth and regeneration. Satellite cells normally remain
quiescent, but activate upon muscle injury or exercise and undergo
asymmetrical division, leading to self-renewal of the stem cell pop-
ulation and production ofmyogenic cells that differentiate into new
muscle ﬁbers. Satellite cells were found to be depleted in the skel-
etal muscle tissue of aMEGF10myopathy patient [2]. Concordantly,
it was reported that MEGF10 overexpression in C2C12 myoblasts
enhances cell proliferation and that knockdown of MEGF10 in mus-
cle ﬁbers leads to a reduction of satellite cells due to premature dif-
ferentiation [4]. MEGF10 is also highly expressed in the central
nervous system [5]. In neuronal tissue, MEGF10 has been reported
to play roles in neuronal cell engulfment [6,7], amyloid-b protein
uptake [8] and retinal neuron spacing [9].
MEGF10 is a single transmembrane protein that has 17 EGF-like
domains in the extracellular N-terminus and a C-terminalin signal transduction [10]. MEGF10 has two mammalian homo-
logues, MEGF11 and MEGF12 (also known as PEAR1 and Jedi-1),
and one orthologue in Drosophila melanogaster, draper. Tyrosine
phosphorylation of MEGF11 andMEGF12 has been reported to con-
tribute to platelet activation [11,12] and glial phagocytosis of apop-
totic neurons [6,7,13], and tyrosine phosphorylation signaling of
draper is important for phagocytic activity [13,14]. Recently, it
has also been reported that MEGF10 and MEGF12 are tyrosine
phosphorylated and regulate phagocytosis of apoptotic neurons
via the Src family kinase-Syk pathway [7]; similar phosphorylation
and regulation patterns have been reported for draper [11,14]. We
hypothesized that MEGF10 participates in a signaling pathway that
is important for satellite cell function. However, there have been no
studies of MEGF10 signaling inmuscle and little is known about the
mechanism of disease for MEGF10 myopathy.
To date, MEGF10 myopathy has been reported in 7 families
from different populations (Fig 1A) [2,3,15]. First, ﬁve families
were reported to possess various homozygous nonsense mutations
or compound heterozygous nonsense and missense mutations, all
showing severe phenotypes [2]. In one of these severely-affected
families, a heterozygous C774Rmutation was paired with a hetero-
zygous P442HfsX9 nonsense mutation. Three of the patients died
in infancy due to respiratory complications. Later, we reported a
sixth family with a milder phenotype who harbored the compound
heterozygous missense mutations C326R and C774R, located at the
second cysteine of the 6th EGF-like domain and the 4th cysteine of
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Fig. 1. Tyrosine phosphorylation in C326R and C774R mutant MEGF10. (A) Diagram of the MEGF10 protein domains with arrows indicating previously reported human
patient’s mutations [2,3,15]. Upper mutations are from individuals with severe disease phenotypes. Lower mutations are from three patients in one family with a mild
phenotype. Note that the C774R mutation has been associated with both severe and mild phenotypes. EGF: EGF-like domain, TM: transmembrane domain, Y: tyrosine
residue. (B) HEK293T cells were transfected with wild type, C326R mutant, and C774R mutant MEGF10 tagged with V5. Cell lysates were immunoprecipitated with anti-V5
antibody, then subjected to immunoblotting with anti-phosphotyrosine (P-Tyr) antibody or anti-V5 antibody. The C774R mutant shows a greater defect in tyrosine
phosphorylation than the C326R mutant. IP V5: V5 tagged immunoprecipitated lysates. Western blot densitometry of the bands shows decreased tyrosine phosphorylation in
C326R and C774R. Quantitative analysis was normalized against intensities of immunoprecipitated V5 bands (data are relative to wild type MEGF10, n = 5). (C) Wild type,
C326R mutant, and C774R mutant MEGF10 constructs were transfected into 293T cells. One day after transfection, cells were ﬁxed and stained with anti-V5 antibody (green).
Representative cells are shown. The left column shows MEGF10 staining with anti-V5 antibody. The right column shows merged images of DAPI-labeled nuclei (blue) with the
images on the left. Mutant proteins show the same subcellular localization pattern as the wild type proteins. Scale bar: 10 lm.
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viduals in this family are now in their third decade, and one is still
ambulatory. They have milder respiratory complications than the
initial cohort of 5 families, only requiring non-invasive nocturnal
ventilatory support. These observations suggest that the C774R
mutation is as deleterious as a nonsense mutation, while the
C326R mutation may be less consequential. Recently, a seventh
family with a homozygous frameshift deletion of exon 7 inMEGF10
was reported to display a severe phenotype [15].
The current study investigates the tyrosine phosphorylation
signaling of MEGF10, using constructs representing the C326R
and C774R mutations and tyrosine phosphorylation deﬁcient
mutations. MEGF10 tyrosine phosphorylation contributes to
MEGF10-induced muscle cell proliferation, potentially explaining
the loss-of-function mechanism of this disease.
2. Material and methods
2.1. Construction of expression vectors for MEGF10 and mutants
The V5-tag sequence was inserted into XhoI- and XbaI-sites in
pCS2(+). The human MEGF10 cDNA was cloned by PCR using the
TOPO TA Cloning Kit (Life Technologies Corporation) then
subcloned into pCS2(+)-V5. Human c-Src cDNA was generously
provided by Professor Shoichi Ishiura (The University of Tokyo,
Tokyo, Japan). The Myc-tagged c-Src was generated by subcloningc-Src into pcDNA3.1-Myc vector (Life Technologies Corporation).
Various MEGF10 mutants, including C326R, C774R, Y1030F and
Y1030D, deletion mutants, and the kinase-inactive dominant neg-
ative variant of c-Src (K298R) [16] were generated by site-directed
mutagenesis as previously described [17]. Primers used in this
study are listed in Supplementary Table 1.
2.2. Cell culture
Human embryonic kidney (HEK) 293T cells (GenHunter Corpo-
ration) and mouse myoblast C2C12 cells (American Type Culture
Collection) were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Life Technologies Corporation) supplemented with 10%
and 20% fetal bovine serum (FBS, Atlanta Biologicals) respectively,
penicillin (100 units/ml, Sigma), and streptomycin (100 lg/ml, Sig-
ma). All cells were maintained in a 5% CO2 incubator at 37 C.
2.3. Immunoprecipitation
The constructs were transfected into HEK293T cells or C2C12
cells using Lipofectamine 2000 reagent (Life Technologies Corpora-
tion) and Fugene HD (Promega), respectively, according to the
manufacturer’s protocols. Cells were collected 24 h after transfec-
tion and lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM phenyl-
methylsulfonyl ﬂuoride, 50 mM NaF, 1 mM Na3VO4) containing a
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(Roche). Protein was immunoprecipitated by either anti-V5 mono-
clonal antibody (Life Technologies Corporation) or anti-Myc mono-
clonal antibody (Life Technologies Corporation) using Protein G
Sepharose 4 Fast Flow (GE Healthcare Life Science). Immunopre-
cipitants were eluted with SDS–PAGE sample buffer (125 mM
Tris-HCl pH 6.8, 5% 2-mercaptoethanol, 2% SDS, 10% glycerol,
0.01% bromophenol blue), boiled at 100 C for 5 min and subjected
to western blot analysis. NuPage Tris-acetate 8-10% gels (Life Tech-
nologies Corporation) were used for the assays. The proteins were
transferred to polyvinylidene ﬂuoride (PVDF) membranes
(Millipore), then blocked with 5% non-fat dry milk (Labscientiﬁc)
or 2.5% bovine serum albumin in Tris-buffered saline (25 mM
Tris-HCl pH 7.4, 137 mM NaCl, 2.7 mM KCl) containing 0.05%
Tween 20 (Sigma). For detection of the V5 and Myc tags, the
proteins were incubated overnight at 4 C using anti-V5 and anti-
Myc antibodies at a 1:2000 dilution. Tyrosine phosphorylation of
MEGF10 was detected by incubation overnight at 4 C using PY20
antibody (BD Bioscience) at a 1:2000 dilution. After incubation
for 1 h at room temperature with horseradish peroxidase (HRP, Life
Technologies Corporation) conjugated anti-mouse IgG antibody,
the bands were visualized by Immobilon Western Chemilumines-
cence HRP Substrate (Millipore) and analyzed by Universal Hood
II Gel Imager (Bio-Rad Laboratories).
2.4. Immunoﬂuorescence analysis
C2C12 and 293T cells were grown on plastic slide chambers and
transfected with wild type MEGF10, C326R mutants, or C774R mu-
tants using Lipofectamine 2000 (Life Technologies Corporation).
The cells were washed with phosphate-buffered saline (PBS), ﬁxed
for 10 min in 4% paraformaldehyde at room temperature, then
permeabilized with 0.25% Triton-X in PBS. After blocking with 5%
goat serum in 2% BSA, the cells were incubated at room tempera-
ture with anti-V5 antibody for 1 h. After 4 washes with PBS, the
cells were incubated with Alexa-488 conjugated goat anti-mouse
antibody with 40 6-diamidino-2-phenylindole (DAPI). Confocal
images were obtained using an LSM 700 laser scanning confocal
microscope (Carl Zeiss) with a 63X 1.4 NA objective using Zen im-
age acquisition software (Carl Zeiss). Images were processed using
Image J software and Adobe Photoshop (Adobe Systems).
2.5. Lentiviral vectors
V5-tagged wild type MEGF10, Y1030F mutant MEGF10, and
Y1030D mutant MEGF10 were subcloned from pCS2(+)-V5 vectors
into lentiviral expression vectors (pCDH-CuO-MCS-EF1-IRES-GFP;
System Biosciences Inc.) using XbaI and NotI sites. Lentiviral vector
production and infection were performed as previously described
[18]. Brieﬂy, lentiviral vectors along with third-generation lentivi-
ral packaging plasmids (MDL/RRE, Rev and VSV-G) were transfec-
ted into HEK293T cells that were grown in 100 mm dishes in
DMEM containing 10% FBS using Lipofectamine 2000 reagent (Life
Technologies Corporation) according to the manufacturer’s proto-
col. Lentivirus-containing media were ﬁltered through 45 lm ﬁl-
ters and concentrated by 40% PEG solution, then pelleted by
centrifugation at 2600g for 45 min at 4 C. Lentiviral infection
was done at a viral titer of more than 1  109 TU/ml.
2.6. Cell proliferation assay
C2C12 myoblasts were infected 1 day after plating with lentiv-
iral vectors expressing wild type MEGF10, Y1030F mutant
MEGF10, Y1030D mutant MEGF10, or empty vector and subjected
to cell proliferation assays. C2C12 myoblasts were seeded at 12500
cells in 60 mm dishes. The number of cells over an approximately1 cm2 growth area was counted in 4 randomly selected areas at 24,
48 and 72 h after plating. To avoid the effect of contact inhibition,
cell counts were performed prior to conﬂuence. Numbers of viable
cells were also assessed 48 h after plating by the CellTiter 96 Aque-
ous One Solution Cell Proliferation Assay (Promega) according to
the manufacturer’s protocol.
2.7. Statistical analysis
Data are presented as mean ± standard deviation. Mean differ-
ences were statistically analyzed by t-test using R software version
2.11.0.3. Results
3.1. The C774R mutation is associated with greater impairment of
MEGF10 tyrosine phosphorylation than the C326R mutation
Most of the disease-causing mutations in MEGF10 reported to
date are nonsense mutations [2,15], but we have also reported
two missense mutations, C326R and C774R, in the extracellular do-
main of MEGF10 (Fig. 1A) [3]. To determine whether tyrosine phos-
phorylation status of MEGF10 is affected by these mutations, the
C326R and C774R mutants were overexpressed in HEK293T cells
and C2C12 cells. Mutant proteins were immunoprecipitated with
anti-V5 antibodies and subjected to Western blot analysis with
anti-phosphotyrosine antibodies (PY20) to assess tyrosine phos-
phorylation status. In both cell lines, wild type MEGF10 protein
was tyrosine-phosphorylated. Tyrosine phosphorylation was se-
verely decreased in the C774R mutant and mildly decreased in
the C326R mutant (Fig. 1B, Supplementary Fig. 1A). To test for
the possibility that this tyrosine phosphorylation involves a differ-
ent protein that interacts with MEGF10 and has a similar molecular
weight, we performed reciprocal immunoprecipitation using anti-
phosphotyrosine (PY20) antibody. MEGF10 was immunoprecipi-
tated with anti-phosphotyrosine antibody, conﬁrming that
MEGF10 is the protein that is tyrosine phosphorylated (Supple-
mentary Fig. 2).
Wild type MEGF10 showed a broad band in a 3–8% gradient gel,
suggesting the presence of glycosylation (Fig. 1B). C774R mutant
MEGF10 showed a thinner band compared to the wild type protein,
suggesting that the defective tyrosine phosphorylation associated
with the C774R mutation may be related to reduced glycosylation.
Overexpressed wild type and C774R mutant MEGF10 were treated
with N-glycosidase. The treated proteins showed similarly sized
bands, migrating at 100 kDa, also suggesting that C774R has less
N-glycosylation (Supplementary Fig. 3).
We analyzed the subcellular localization of MEGF10 in
HEK293T and C2C12 cells to evaluate the possibility that either
the C326R or C774R mutation alters protein localization. MEGF10
has been shown to localize to the plasma membrane [19]. Immu-
noﬂuorescent staining of V5 tagged-MEGF10 shows a lattice-like
pattern at the adherent surface between the cells and the tissue
culture dish, in concurrence with a previous report [19]. Mutant
C326R and C774R MEGF10 display the same subcellular localiza-
tion patterns as wild type MEGF10 in both HEK293T and C2C12
cells, suggesting that the phosphorylation defects of these mutant
MEGF10 proteins is not due to aberrant subcellular localization
(Fig. 1C, Supplementary Fig. 1B).
3.2. MEGF10 is tyrosine phosphorylated at Y1030 by c-Src
MEGF10 has multiple potential tyrosine phosphorylation sites
in its cytoplasmic domain. It is not fully understood which tyrosine
residues may be involved in phosphorylation signaling. To identify
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fected into HEK293T cells were initially screened. The MEGF10-
deletion 1 mutant with a deletion from the Y879 to Y1002 amino
acid residues showed slightly decreased tyrosine phosphorylation
as compared to wild type MEGF10. On the contrary, the MEGF10-
deletion mutant 2 with a deletion of the Y1016 to Y1099 amino
acid residues showed complete loss of tyrosine phosphorylation
(Fig. 2A). This indicated that MEGF10 has an important tyrosine
phosphorylation site between Y1016 and Y1099. A series of tyro-
sine-to-phenylalanine mutants in this range were generated and
then overexpressed in HEK293T cells. Among these, only the
Y1030F mutant lost tyrosine phosphorylation, suggesting that
Y1030 is a major tyrosine phosphorylation site for MEGF10
(Fig. 2B). MEGF10 phosphorylation was also ablated when the
Y1030F mutant was expressed in C2C12 myoblasts (Supplemen-
tary Fig. 1A). Y1030 is well conserved in many vertebrate species
and has comparable residues in MEGF11 (Y944) and MEGF12/
PEAR1/Jedi-1 (Y925) (Fig. 2C).
The MEGF10 homologue MEGF12/PEAR1/Jedi-1 is phosphory-
lated by c-Src at Y925 [11]. To further characterize the MEGF10
tyrosine phosphorylation signaling mechanism, we co-transfected
wild type MEGF10 with Myc-tagged c-Src, dominant negative ki-
nase-dead c-Src (c-Src K298R) or empty vector control into
HEK293T cells. Wild type MEGF10 co-expressed with c-Src showed
a marked increase in tyrosine phosphorylation compared to wild
type MEGF10 co-expressed with empty vector (Fig. 2D, Supple-
mentary Fig. 4). In addition, co-expression of wild type MEGF10
with dominant negative c-Src demonstrated a loss of tyrosine
phosphorylation compared to wild type MEGF10 co-expressed
with empty vector control (Supplementary Fig. 4). These results
indicate that overexpressed MEGF10 is phosphorylated by c-Src.
Wild type, C774R mutant, or Y1030F mutant MEGF10 was then
co-transfected with Myc-tagged c-Src into HEK293T cells.
Co-expression of human c-Src showed markedly enhanced phos-
phorylation of wild type MEGF10 and weakly enhanced phosphor-
ylation of the C774R mutant. The Y1030F mutant showed reduced
but not absent phosphorylation in the presence of c-Src compared
to wild type or C774R MEGF10, indicating that c-Src primarily
phosphorylates Y1030, but may also phosphorylate other tyrosine
residues when overexpressed (Fig. 2D). These other tyrosine
residues may not be phosphorylated under physiological normal
conditions, as the Y1030F mutant showsmarkedly decreased phos-
phorylation without overexpression of c-Src (Fig. 2B and D). It is
also possible that Y1030 needs to be phosphorylated ﬁrst, initiating
a signaling event that leads to the other residues being phosphor-
ylated. In addition, overexpressed c-Src was able to co-immuno-
precipitate with MEGF10, suggesting that c-Src associates with
MEGF10 (Fig. 2D, Supplementary Fig. 4). This association was de-
creased when kinase-dead c-Src was overexpressed with wild type
MEGF10 (Supplementary Fig. 4) or when c-Src was overexpressed
with C774R or Y1030F mutant MEGF10 (Fig. 2D), suggesting that
c-Src binding to MEGF10 correlates with tyrosine phosphorylation
of this protein.
3.3. MEGF10 tyrosine phosphorylation is important for muscle cell
proliferation
Overexpression of MEGF10 increases C2C12 cell proliferation
[4]. To evaluate whether MEGF10 phosphorylation at Y1030 is in-
volved in muscle cell proliferation signaling, we overexpressed
wild type, Y1030F mutant, or Y1030D mutant MEGF10, with an
empty vector control, in C2C12 myoblasts using lentiviral vectors
(Fig. 3A). Overexpression of wild type MEGF10 increased cell pro-
liferation, in concordance with a previous report [4]. This effect
was nulliﬁed in the Y1030F mutant overexpressing myoblasts.
The phosphorylation-mimicking mutant Y1030D and wild typeMEGF10 showed similar increased cell proliferation when overex-
pressed in myoblasts, suggesting that wild type MEGF10 is
phosphorylated in proliferating myoblasts (Fig. 3B). A cell viability
assay and a proliferation marker Ki-67 positive cell count con-
ﬁrmed that overexpression of wild type MEGF10 and the Y1030D
mutant increases cell proliferation in C2C12 myoblasts, whereas
the overexpressed Y1030F mutant did not (Fig. 3C, Supplementary
Fig. 5). These results suggest that MEGF10 tyrosine phosphoryla-
tion at Y1030 signaling enhances myoblast cell proliferation.4. Discussion
MEGF10 myopathy is the ﬁrst human skeletal muscle disease
caused by defects in a protein that is primarily expressed in muscle
satellite cells [2–4]. Muscle satellite cells are progenitor cells that
are necessary for repair of skeletal muscle ﬁbers. In mice, satellite
cell depletion has been shown to cause defective postnatal muscle
growth, failure of muscle regeneration and also mild muscle atro-
phy over time in uninjured muscle [20–24]. Satellite cells were
found to be absent in the muscle tissue of a patient with MEGF10
myopathy [2]. Consistent with these observations in human sub-
jects and a previous report [4], we showed that MEGF10 overex-
pression increased C2C12 myoblast proliferation while a tyrosine
phosphorylation defective mutant version of MEGF10 did not. In
addition, tyrosine phosphorylation of C326R and C774R MEGF10
mutant proteins was reduced in patterns that are consistent with
observations of genotype-phenotype correlations in the human
disease. These results suggest that MEGF10 myopathy may be
caused by a defect in muscle satellite cell proliferation due to im-
paired MEGF10 tyrosine phosphorylation signaling. Our data, in
conjunction with reports that c-Src positively regulates C2C12 cell
proliferation [25,26] and that overexpression of MEGF10 has been
reported to increase C2C12 cell proliferation [4] suggest that c-Src
may regulate muscle cell proliferation through the process of
MEGF10 tyrosine phosphorylation.
MEGF10 has 17 EGF-like domains but little is known about the
role of these domains in MEGF10 function. We hypothesized that
the conformations of certain EGF-like domains of MEGF10 are
important for transmitting extracellular signals. Both the C326R
and C774R mutations are expected to disrupt the second disulﬁde
bond of their respective EGF-like domains, but C326R results in a
milder effect both biochemically and clinically than C774R, sug-
gesting that the 16th EGF-like domain may be more important for
recognizing extracellular stimuli and conducting signals than the
6th EGF-like domain. In addition, glycosylation of extracellular do-
mains of EGFR is known to be important for receptor-ligand binding
[27,28]. We observed that glycosylation is decreased in the C774R
mutant compared to wild type and C326R MEGF10. MEGF10 glyco-
sylation may also be involved in MEGF10 signal transduction.
Our experimental results indicate that MEGF10 transduces
extracellular stimuli to the intracellular tyrosine-rich domain and
participates in signal transduction pathways. Tyrosine phosphory-
lation of some immunoreceptors by Src family kinases (SFKs) re-
sults in recruitment of Syk kinase, which in turn mediates
downstream signaling pathways [29]. MEGF10, MEGF12/PEAR1/
Jedi-1, and their Drosophila orthologue draper participate in
neuronal corpus engulfment signaling [7,13,14] via a similar tyro-
sine phosphorylation-SFKs-Syk cascade. We showed that c-Src
associates with MEGF10 in a tyrosine-phosphorylation-dependent
manner. Our data suggest that c-Src augments the phosphorylation
of MEGF10 and helps form a signaling complex. It is not yet known
what signaling molecules MEGF10 recruits or what ligand initiates
MEGF10 signaling. Further studies will uncover further details
regarding this signaling pathway that may play an important role
in muscle cell proliferation.
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2956 S. Mitsuhashi et al. / FEBS Letters 587 (2013) 2952–2957We have demonstrated that among two disease-causing muta-
tions in MEGF10, one is associated with more signiﬁcant impair-
ment of MEGF10 tyrosine phosphorylation than the other.
Additionally, we have shown that MEGF10 tyrosine phosphoryla-
tion at Y1030 is important for muscle cell proliferation. Our work
suggests that defects in the MEGF10 signaling cascade may deplete
muscle satellite cells, possibly contributing to the MEGF10 myop-
athy disease process. Further characterization of this pathway
may enrich our understanding of muscle homeostasis. Elucidating
the mechanism of MEGF10myopathymay yield newmolecular ap-
proaches for muscle cell proliferation which is important for mus-
cle regeneration, paving the way for potential new therapies for avariety of muscle diseases, including MEGF10 myopathy itself and
other muscle diseases.
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